Evidence map›Paper›PMID 39170029›Full record

ReviewSichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition2024

[Advances in the Application of Nanozymes in Joint Disease Therapy].

Jia Zeng, Songya Huang, Fangxue DU, Sujiao Cao, Yang Gao, Li Qiu, Yuanjiao Tang

Abstract readReviewEnglish Abstract
In one paragraph

Review in Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Jia Zeng- ( 610200) Department of Ultrasound, The First People's Hospital of Shuangliu District, Chengdu & West China (Airport) Hospital, Sichuan University, Chengdu 610200, China.
Songya Huang- ( 610200) Department of Ultrasound, The First People's Hospital of Shuangliu District, Chengdu & West China (Airport) Hospital, Sichuan University, Chengdu 610200, China.
Fangxue DU- ( 610200) Department of Ultrasound, The First People's Hospital of Shuangliu District, Chengdu & West China (Airport) Hospital, Sichuan University, Chengdu 610200, China.
Sujiao Cao- ( 610200) Department of Ultrasound, The First People's Hospital of Shuangliu District, Chengdu & West China (Airport) Hospital, Sichuan University, Chengdu 610200, China.
Yang Gao- ( 610200) Department of Ultrasound, The First People's Hospital of Shuangliu District, Chengdu & West China (Airport) Hospital, Sichuan University, Chengdu 610200, China.
Li Qiu- ( 610200) Department of Ultrasound, The First People's Hospital of Shuangliu District, Chengdu & West China (Airport) Hospital, Sichuan University, Chengdu 610200, China.
Yuanjiao Tang- ( 610200) Department of Ultrasound, The First People's Hospital of Shuangliu District, Chengdu & West China (Airport) Hospital, Sichuan University, Chengdu 610200, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Nanozymes are nanoscale materials with enzyme-mimicking catalytic properties. Nanozymes can mimic the mechanism of natural enzyme molecules. By means of advanced chemical synthesis technology, the size, shape, and surface characteristics of nanozymes can be accurately regulated, and their catalytic properties can be customized according to the specific need. Nanozymes can mimic the function of natural enzymes, including catalase (CAT), superoxide dismutase (SOD), and glutathione peroxidase (GPx), to scavenge reactive oxygen species (ROS). Reported findings have shown that nanozymes have the advantages of excellent stability, low cost, and adjustable catalytic activity, thereby showing great potential and broad prospects in the application of disease treatment. Herein, we reviewed the advances in the application of nanozymes in the treatment of joint diseases. The common clinical manifestations of joint diseases include joint pain, swelling, stiffness, and limited mobility. In severe cases, joint diseases may lead to joint destruction, deformity, and functional damage, entailing crippling socioeconomic burdens. ROS is a product of oxidative stress. Increased ROS in the joints can induce macrophage M1 type polarization, which in turn induces and aggravates arthritis. Therefore, the key to the treatment of joint diseases lies in ROS scavenging and increasing oxygen (O

Indexed as

Joint DiseasesReactive Oxygen SpeciesCatalaseGlutathione PeroxidaseHumansNanostructuresOxidative StressSuperoxide DismutaseCatalaseGlutathione PeroxidaseReactive Oxygen SpeciesSuperoxide DismutaseApplication progressArthritisNanozymeReactive oxygen species

Identifiers

PMID39170029
PMCPMC11334270

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.